Provista’s BT Test, a new blood test to aid healthcare providers in early breast cancer detection, will be provided through International Health Technology’s (IHT) women’s clinic for breast health, BreastHealth UK.
Provista and IHT will introduce the BT Test into the UK and Ireland beginning this summer with a following expanded release to other EU countries thereafter.
The BT Test or Biomarker Translation Test finds multiple cancer-related proteins in the blood and combines the results with the patient’s medical profile to help physicians in their efforts to find breast cancer as early as possible.
William Gartner, President and CEO of Provista, said: “Partnering with IHT and their BreastHealth UK clinics allows us to expand the availability of the BT Test to women and physicians in the UK and other EU countries.”